Cargando…

Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis

Radiolabeled peptides possessing an Arg-Gly-Asp (RGD) motif are widely used radiopharmaceuticals for PET imaging of tumor angiogenesis due to their high affinity and selectivity to α(v)β(3) integrin. This receptor is overexpressed in tumor and tumor endothelial cells in the case of numerous cancer c...

Descripción completa

Detalles Bibliográficos
Autores principales: Gyuricza, Barbara, Szabó, Judit P., Arató, Viktória, Szücs, Dániel, Vágner, Adrienn, Szikra, Dezső, Fekete, Anikó
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227980/
https://www.ncbi.nlm.nih.gov/pubmed/34073528
http://dx.doi.org/10.3390/pharmaceutics13060796
_version_ 1783712635131265024
author Gyuricza, Barbara
Szabó, Judit P.
Arató, Viktória
Szücs, Dániel
Vágner, Adrienn
Szikra, Dezső
Fekete, Anikó
author_facet Gyuricza, Barbara
Szabó, Judit P.
Arató, Viktória
Szücs, Dániel
Vágner, Adrienn
Szikra, Dezső
Fekete, Anikó
author_sort Gyuricza, Barbara
collection PubMed
description Radiolabeled peptides possessing an Arg-Gly-Asp (RGD) motif are widely used radiopharmaceuticals for PET imaging of tumor angiogenesis due to their high affinity and selectivity to α(v)β(3) integrin. This receptor is overexpressed in tumor and tumor endothelial cells in the case of numerous cancer cell lines, therefore, it is an excellent biomarker for cancer diagnosis. The galectin-3 protein is also highly expressed in tumor cells and N-acetyllactosamine is a well-established ligand of this receptor. We have developed a synthetic method to prepare a lactosamine-containing radiotracer, namely (68)Ga-NODAGA-LacN-E[c(RGDfK)](2), for cancer diagnosis. First, a lactosamine derivative with azido-propyl aglycone was synthetized. Then, NODAGA-NHS was attached to the amino group of this lactosamine derivative. The obtained compound was conjugated to an E[c(RGDfK)](2) peptide with a strain-promoted click reaction. We have accomplished the radiolabeling of the synthetized NODAGA-LacN-E[c(RGDfK)](2) precursor with a positron-emitting (68)Ga isotope (radiochemical yield of >95%). The purification of the labeled compound with solid-phase extraction resulted in a radiochemical purity of >99%. Subsequently, the octanol–water partition coefficient (log P) of the labeled complex was determined to be −2.58. In addition, the in vitro stability of (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) was investigated and it was found that it was stable under the examined conditions.
format Online
Article
Text
id pubmed-8227980
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82279802021-06-26 Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis Gyuricza, Barbara Szabó, Judit P. Arató, Viktória Szücs, Dániel Vágner, Adrienn Szikra, Dezső Fekete, Anikó Pharmaceutics Article Radiolabeled peptides possessing an Arg-Gly-Asp (RGD) motif are widely used radiopharmaceuticals for PET imaging of tumor angiogenesis due to their high affinity and selectivity to α(v)β(3) integrin. This receptor is overexpressed in tumor and tumor endothelial cells in the case of numerous cancer cell lines, therefore, it is an excellent biomarker for cancer diagnosis. The galectin-3 protein is also highly expressed in tumor cells and N-acetyllactosamine is a well-established ligand of this receptor. We have developed a synthetic method to prepare a lactosamine-containing radiotracer, namely (68)Ga-NODAGA-LacN-E[c(RGDfK)](2), for cancer diagnosis. First, a lactosamine derivative with azido-propyl aglycone was synthetized. Then, NODAGA-NHS was attached to the amino group of this lactosamine derivative. The obtained compound was conjugated to an E[c(RGDfK)](2) peptide with a strain-promoted click reaction. We have accomplished the radiolabeling of the synthetized NODAGA-LacN-E[c(RGDfK)](2) precursor with a positron-emitting (68)Ga isotope (radiochemical yield of >95%). The purification of the labeled compound with solid-phase extraction resulted in a radiochemical purity of >99%. Subsequently, the octanol–water partition coefficient (log P) of the labeled complex was determined to be −2.58. In addition, the in vitro stability of (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) was investigated and it was found that it was stable under the examined conditions. MDPI 2021-05-26 /pmc/articles/PMC8227980/ /pubmed/34073528 http://dx.doi.org/10.3390/pharmaceutics13060796 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gyuricza, Barbara
Szabó, Judit P.
Arató, Viktória
Szücs, Dániel
Vágner, Adrienn
Szikra, Dezső
Fekete, Anikó
Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis
title Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis
title_full Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis
title_fullStr Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis
title_full_unstemmed Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis
title_short Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis
title_sort synthesis of novel, dual-targeting (68)ga-nodaga-lacn-e[c(rgdfk)](2) glycopeptide as a pet imaging agent for cancer diagnosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227980/
https://www.ncbi.nlm.nih.gov/pubmed/34073528
http://dx.doi.org/10.3390/pharmaceutics13060796
work_keys_str_mv AT gyuriczabarbara synthesisofnoveldualtargeting68ganodagalacnecrgdfk2glycopeptideasapetimagingagentforcancerdiagnosis
AT szabojuditp synthesisofnoveldualtargeting68ganodagalacnecrgdfk2glycopeptideasapetimagingagentforcancerdiagnosis
AT aratoviktoria synthesisofnoveldualtargeting68ganodagalacnecrgdfk2glycopeptideasapetimagingagentforcancerdiagnosis
AT szucsdaniel synthesisofnoveldualtargeting68ganodagalacnecrgdfk2glycopeptideasapetimagingagentforcancerdiagnosis
AT vagneradrienn synthesisofnoveldualtargeting68ganodagalacnecrgdfk2glycopeptideasapetimagingagentforcancerdiagnosis
AT szikradezso synthesisofnoveldualtargeting68ganodagalacnecrgdfk2glycopeptideasapetimagingagentforcancerdiagnosis
AT feketeaniko synthesisofnoveldualtargeting68ganodagalacnecrgdfk2glycopeptideasapetimagingagentforcancerdiagnosis